BACKGROUND: The current study was conducted to investigate whether patients with familial combined hyperlipidaemia (FCHL ) are predisposed to the development of type 2 diabetes mellitus (T2DM). METHODS: A cohort of 56 FCHL patients and 54 spouses was followed over time with a five-year interval. Diagnosis of T2DM was based on fasting glucose levels or use of antidiabetic medication. Baseline body mass index, waist circumference, blood pressure, use of antihypertensive and lipid-lowering medication, plasma cholesterol, triglycerides, apolipoprotein B, glucose, insulin and alanine aminontransferase (ALAT) levels were determined as potential predictors of new onset T2DM. RESULTS: Baseline prevalence of T2DM was 2% in spouses and 9% in FCHL patients, and 4 and 20%, respectively, after five-year follow-up. The incidence of T2DM was significantly higher in FCHL patients (2 vs 14%; OR 9.1; 95% CI 1.0 to 81.4; p=0.04; age and sex adjusted). Of all baseline variables, only plasma insulin levels (not glucose) significantly predicted the development of T2DM (p=0.04). CONCLUSION: The present study is the first to present incidence numbers of T2DM in FCHL and demonstrates that FCHL patients, as compared with healthy controls, are predisposed to the development of T2DM. This is - at least in part - accounted for by an increased insulin resistance.
BACKGROUND: The current study was conducted to investigate whether patients with familial combined hyperlipidaemia (FCHL ) are predisposed to the development of type 2 diabetes mellitus (T2DM). METHODS: A cohort of 56 FCHL patients and 54 spouses was followed over time with a five-year interval. Diagnosis of T2DM was based on fasting glucose levels or use of antidiabetic medication. Baseline body mass index, waist circumference, blood pressure, use of antihypertensive and lipid-lowering medication, plasma cholesterol, triglycerides, apolipoprotein B, glucose, insulin and alanine aminontransferase (ALAT) levels were determined as potential predictors of new onset T2DM. RESULTS: Baseline prevalence of T2DM was 2% in spouses and 9% in FCHL patients, and 4 and 20%, respectively, after five-year follow-up. The incidence of T2DM was significantly higher in FCHL patients (2 vs 14%; OR 9.1; 95% CI 1.0 to 81.4; p=0.04; age and sex adjusted). Of all baseline variables, only plasma insulin levels (not glucose) significantly predicted the development of T2DM (p=0.04). CONCLUSION: The present study is the first to present incidence numbers of T2DM in FCHL and demonstrates that FCHL patients, as compared with healthy controls, are predisposed to the development of T2DM. This is - at least in part - accounted for by an increased insulin resistance.
Authors: M M J van Greevenbroek; S Ghosh; C J H van der Kallen; M C G J Brouwers; C G Schalkwijk; C D A Stehouwer Journal: J Clin Endocrinol Metab Date: 2012-10-09 Impact factor: 5.958
Authors: Nanda Gruben; Anouk Funke; Niels J Kloosterhuis; Marijke Schreurs; Fareeba Sheedfar; Rick Havinga; Sander M Houten; Ronit Shiri-Sverdlov; Bart van de Sluis; Jan Albert Kuivenhoven; Debby P Y Koonen; Marten H Hofker Journal: J Diabetes Res Date: 2015-02-28 Impact factor: 4.011
Authors: Giuseppe Mandraffino; Carmela Morace; Maria Stella Franzè; Veronica Nassisi; Davide Sinicropi; Maria Cinquegrani; Carlo Saitta; Riccardo Scoglio; Sebastiano Marino; Alessandra Belvedere; Valentina Cairo; Alberto Lo Gullo; Michele Scuruchi; Giovanni Raimondo; Giovanni Squadrito Journal: Biomedicines Date: 2022-07-22
Authors: Martijn C G J Brouwers; Jacqueline de Graaf; Nynke Simons; Steven Meex; Sophie Ten Doeschate; Shadana van Heertum; Britt Heidemann; Jim Luijten; Douwe de Boer; Nicolaas Schaper; Coen D A Stehouwer; Marleen M J van Greevenbroek Journal: BMJ Open Diabetes Res Care Date: 2020-03